精美幻灯2010美国临床肿瘤学会年会恶性血液病最新进展.pptVIP

June 4-8, 2010Chicago, Illinois;About These Slides;Faculty;An Update on Hematologic Malignancies: Overview;Lymphomas;Untreated patients with high tumor burden follicular lymphoma;PRIMA: Primary Endpoint (PFS) Met at Planned Interim Analysis;PRIMA: Benefits of Rituximab Maintenance by Subgroup;PRIMA: Rituximab Maintenance Associated With Improved Responses;PRIMA: Safety During Rituximab Maintenance;PRIMA: Conclusions;Sureda A, et al. ASCO 2010. Abstract 8007.;Sureda A, et al. ASCO 2010. Abstract 8007. Reprinted with permission.;Sureda A, et al. ASCO 2010. Abstract 8007. Reprinted with permission.;Sureda A, et al. ASCO 2010. Abstract 8007. Reprinted with permission.;Panobinostat in Relapsed/Refractory HL: Conclusions;Gnaoui TE, et al. ASCO 2010. Abstract 8011.;Gnaoui TE, et al. ASCO 2010. Abstract 8011.;Gnaoui TE, et al. ASCO 2010. Abstract 8011.;Gnaoui TE, et al. ASCO 2010. Abstract 8011.;Gnaoui TE, et al. ASCO 2010. Abstract 8011.;Gnaoui TE, et al. ASCO 2010. Abstract 8011.; Chronic Myeloid Leukemia ;Patients with previously untreated chronic-phase CML (N = 519);DASISION: Response Definitions;DASISION: CCyR Rate by 12 Mos (ITT);DASISION: CCyR and MMR Rates Over Time (ITT);DASISION: Patients More Likely to Achieve MMR at Any Time With Dasatinib ;DASISION: Differences in Adverse Events Rates With Dasatinib vs Imatinib;Conclusions;Patients newly diagnosed withPh-positive CP-CML within 6 mos (N = 846);;ENESTnd: CCyR Rates by 12 Mos and Overall (ITT);Larson RA, et al. ASCO 2010. Abstract 6501.; Chronic Myelomonocytic Leukemia;Safety and Efficacy of Azacitidine in CMML ;Azacitidine in CMML: Response and Overall Survival;Azacitidine in CMML: Conclusions; Multiple Myeloma;Updated Analysis of Phase I/II Trial of VRD in Newly Diagnosed Multiple Myeloma;VRD in Newly Diagnosed MM: Patient Disposition at Longer Follow-up;VRD in Newly Diagnosed MM: Updated Outcomes;Responses Associated With Bortezomib, Lenalidomide, Dexamethasone ;Summary;CALGB 100104: Lenalidomide vs